Significance: The use of cancer-targeted contrast agents in fluorescence-guided surgery (FGS) has the potential to improve intraoperative visualization of tumors and surgical margins. However, evaluation of their translational potential is challenging.
Aim: We examined the utility of a somatostatin receptor subtype-2 (SSTR2)-targeted fluorescent agent in combination with a benchtop near-infrared fluorescence (NIRF) imaging system to visualize mouse xenografts under conditions that simulate the clinical FGS workflow for open surgical procedures.
Approach: The dual-labeled somatostatin analog, Ga67-MMC(IR800)-TOC, was injected into mice (n = 24) implanted with SSTR2-expressing tumors and imaged with the customized OnLume NIRF imaging system (Madison, Wisconsin). In vivo and ex vivo imaging were performed under ambient light. The optimal dose (0.2, 0.5, and 2 nmol) and imaging time point (3, 24, 48, and 72 h) were determined using contrast-to-noise ratio (CNR) as the image quality parameter. Video captures of tumor resections were obtained to provide an FGS readout that is representative of clinical utility. Finally, a log-transformed linear regression model was fitted to assess congruence between fluorescence readouts and the underlying drug distribution.
Results: The drug-device combination provided high in vivo and ex vivo contrast (CNRs > 3, except lung at 3 h) at all time points with the optimal dose of 2 nmol. The optimal imaging time point was 24-h post-injection, where CNRs > 6.5 were achieved in tissues of interest (i.e., pancreas, small intestine, stomach, and lung). Intraoperative FGS showed excellent utility for examination of the tumor cavity pre- and post-resection. The relationship between fluorescence readouts and gamma counts was linear and strongly correlated (n = 334, R2 = 0.71; r = 0.84; P < 0.0001).
Conclusion: The innovative OnLume NIRF imaging system enhanced the evaluation of Ga67-MMC(IR800)-TOC in tumor models. These components comprise a promising drug-device combination for FGS in patients with SSTR2-expressing tumors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725236 | PMC |
| http://dx.doi.org/10.1117/1.JBO.25.12.126002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Scale-Up and Postapproval Changes in Orally Inhaled Drug Products: Scientific and Regulatory Considerations.
J Aerosol Med Pulm Drug Deliv
December 2024
Eli Lilly and Company, Indianapolis, Indiana, USA.
Approved drug products may be subject to change(s) for a variety of reasons. The changes may include, but are not limited to, increase in batch size, alteration of the drug product constituent(s), improvement in the manufacturing process, and shift in manufacturing sites. The extent of pharmaceutical testing and the regulatory pathway for timely implementation of any change in the approved product and/or process depends upon the nature and extent of change.
View Article and Find Full Text PDFDrug-device-field integration for mitochondria-targeting dysfunction and tumor therapy by home-tailored pyroelectric nanocomposites.
Biomaterials
May 2025
Department of Cardiology, Tianjin Chest Hospital, Tianjin, 300222, China.
In spite of the hypoxia tumor microenvironment, an efficacious treatment with minimal invasiveness is highly desirable. Among common cellular organelles, mitochondria is a common target for inductive cellular apoptosis and tumor proliferation inhibition. Nevertheless, tumor hypoxic circumstances always give rise to poor therapeutic efficiency and instead lead to lesion recurrence and unsatisfactory prognosis.
View Article and Find Full Text PDFThe intersection of prescription drugs and medical devices: the evaluation and funding challenges of two categories of emerging health technologies.
Int J Technol Assess Health Care
November 2024
Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Health technology assessments (HTAs) are policy analysis frameworks contributing to the approval, reimbursement, and rollout of biotechnology and pharmaceuticals. New innovations in health technologies expose gaps in reimbursement and implementation guidelines. We defined two types of emerging health technologies: (1) therapeutic innovations, such as drug-device combination products or nondrug alternatives to prescription drugs and (2) disruptive health innovations such as novel surgeries and gene replacement therapies.
View Article and Find Full Text PDFArticle Synopsis
- * The ASCEND trial included adults aged 18-65 who had a history of migraines, and participants could self-administer the drug up to 12 times a month for their attacks.
- * Results showed that 14.3% of migraine attacks treated with STS101 led to mild or moderate side effects, while the drug effectively reduced pain quickly, achieving significant relief within 24 hours in many cases.
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products.
MAbs
September 2024
Delivery Systems, Ypsomed AG, Burgdorf, Switzerland.
Article Synopsis
- Subcutaneous (SC) administration is changing how biopharmaceuticals are delivered, enabling patients to manage treatments at home, especially through larger doses that decrease the frequency of injections.* -
- A study reviewed 182 large-volume SC biopharmaceuticals, mostly monoclonal antibodies, targeting a range of diseases, with cancer treatments typically administered by professionals and non-cancer treatments often self-administered.* -
- The research highlights a growing pipeline for SC-administered treatments and emphasizes the need for improved drug delivery systems to support less frequent injections, aiding in product development and market strategies.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!